China Healthwise Holdings (0348) AI Stock Analysis

• Market Cap: HK$102.47M
• Dividend Yield: N/A
• Average Volume (3M): 796.76K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.10
• Revenue Growth: -22.38%
• EPS Growth: 70.05%
• Country: HK
• Employees: 90
• Sector: Healthcare
• Sector Strength: 48
• Industry: Medical - Pharmaceuticals
• EPS (TTM): -0.01
• Shares Outstanding: 770,480,830
• 10 Day Avg. Volume: 148,600
• 30 Day Avg. Volume: 796,756
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 25 Underperform
• Price Target: ―

China Healthwise Holdings faces substantial financial challenges, including declining revenues and negative equity, which are the most significant factors for the low score. Technical indicators reveal a bearish trend, further affecting the score. The negative P/E ratio and lack of dividends highlight valuation concerns. The cumulative financial and operational issues result in a low overall stock score.

China Healthwise Holdings Business Overview & Revenue Model

Company Description

China Healthwise Holdings Limited (0348) is a Hong Kong-based investment holding company primarily engaged in the manufacturing and sales of toys, as well as the distribution and retail of personal care products and medical supplies. The company operates through two main segments: the Toy Segment and the Personal Care and Health Care Segment. The Toy Segment focuses on the design, development, and distribution of a diverse range of toys, while the Personal Care and Health Care Segment is involved in the distribution of personal care products and medical and healthcare-related supplies.

How the Company Makes Money

China Healthwise Holdings generates revenue through the manufacturing and sales of toys within its Toy Segment, which includes the design, development, and distribution of toys and related products to various markets. Additionally, the company earns income from its Personal Care and Health Care Segment, which involves the distribution and retail of personal care products, as well as medical and healthcare-related supplies. Key revenue streams include wholesale and retail sales, and the company may leverage strategic partnerships with distributors and retailers to expand its market reach. Factors contributing to its earnings include market demand for toys and healthcare products, as well as the company's ability to innovate and adapt to consumer preferences.

China Healthwise Holdings Financial Statement Overview

Summary

China Healthwise Holdings exhibits significant financial instability with declining revenues, persistent losses, and negative equity. Cash flow issues are evident with no free cash flow in the most recent year. The company faces solvency concerns due to negative stockholders' equity and declining operating cash flows.

Income Statement

The company has experienced consistent revenue declines from 2021 to 2024, with a significant drop in net income from -$103 million in 2021 to -$40 million in 2024. Gross profit margin has fallen from 53.5% in 2021 to 30.8% in 2024. The net profit margin and EBIT margin are both negative, indicating ongoing operational challenges.

Balance Sheet

The company has a negative stockholders' equity of -$18.38 million in 2024, indicating potential solvency issues. The debt-to-equity ratio is not applicable due to negative equity, but the overall liabilities exceed assets. The equity ratio is negative, reflecting a concerning balance sheet situation.

Cash Flow

Operating cash flow has significantly declined from $42 million in 2021 to $0 in 2024. Free cash flow was positive in 2023 but dropped to zero in 2024, indicating cash flow management issues. There is no free cash flow growth, and the operating cash flow to net income ratio is unavailable due to zero operating cash flow.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	113.58M	146.32M	142.06M	170.08M	137.85M
Gross Profit	35.00M	60.29M	53.27M	90.99M	61.06M
EBITDA	-20.07M	-117.45M	-45.80M	-89.97M	-45.33M
Net Income	-40.28M	-134.56M	-54.27M	-103.05M	-69.28M
Balance Sheet
Total Assets	122.05M	149.67M	287.66M	314.10M	434.28M
Cash, Cash Equivalents and Short-Term Investments	48.15M	54.28M	73.02M	96.91M	139.92M
Total Debt	103.74M	108.90M	109.90M	90.86M	113.81M
Total Liabilities	140.43M	145.27M	149.01M	121.03M	137.99M
Stockholders Equity	-18.38M	4.40M	138.65M	193.06M	296.29M
Cash Flow
Free Cash Flow	0.00	14.30M	-28.97M	41.72M	7.47M
Operating Cash Flow	-1.79M	14.49M	-28.34M	42.08M	11.99M
Investing Cash Flow	0.00	-191.00K	-631.00K	-360.00K	1.50M
Financing Cash Flow	0.00	-17.04M	5.95M	-36.36M	-25.75M

China Healthwise Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.13
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0348, the sentiment is Positive. The current price of 0.13 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.10, and above the 200-day MA of 0.12, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 59.45 is Neutral, neither overbought nor oversold. The STOCH value of 17.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0348.

China Healthwise Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
0700	79 Outperform	$5.38T	24.15	21.04%	0.75%	11.41%	39.10%
2318	79 Outperform	$1.10T	8.21		4.82%	11.71%	37.04%
1199	74 Outperform	HK$22.12B	8.17	5.64%	4.65%	5.93%	-3.64%
0688	69 Neutral	$155.96B	9.20	4.15%	2.10%	-10.21%	-40.22%
0916	67 Neutral	$114.54B	9.36	8.01%	3.62%	-8.02%	13.82%
Sector *	57 Neutral	£5.54B	4.96	-44.55%	2.27%	28.02%	-9.61%
0348	25 Underperform	HK$102.47M	―	-317.19%	―	-22.38%	70.05%

China Healthwise Holdings Corporate Events

China Healthwise Extends Loan Repayment Date for Customer N

China Healthwise Holdings Limited has announced a supplemental agreement to extend the repayment date for a financial facility provided to Customer N. The loan, amounting to up to HK$9 million, will now be repayable by March 21, 2026. This extension is part of the company’s strategy to manage its financial assistance offerings and maintain flexibility in its lending operations. The terms include an interest rate based on the Hong Kong Dollar Best Lending Rate plus 3%, with no security provided by the borrower. This move may impact the company’s financial operations by potentially increasing its exposure to credit risk, while also offering continued support to its clients.

China Healthwise Holdings Announces Annual General Meeting and Key Resolutions

China Healthwise Holdings Limited has announced its upcoming annual general meeting, scheduled for June 18, 2025, in Hong Kong. The meeting will address several key resolutions, including the re-election of executive and independent non-executive directors, the re-appointment of auditors, and authorizing the board to manage share allotments. These decisions are crucial for the company’s governance and strategic direction, impacting its operational capabilities and stakeholder interests.

China Healthwise Holdings Reports Annual Results for 2024

China Healthwise Holdings Limited reported its annual results for the year ended 31 December 2024, showing a significant decrease in revenue from HK$146,317,000 in 2023 to HK$113,575,000 in 2024. The company experienced a comprehensive loss of HK$40,278,000, which, although substantial, was an improvement from the previous year’s loss of HK$134,251,000, indicating some recovery in its financial performance.

China Healthwise Projects Significant Reduction in FY2024 Losses

China Healthwise Holdings Limited, a company listed on the Hong Kong Stock Exchange, has announced an expected significant decrease in its financial losses for the fiscal year ending December 31, 2024. The company projects a loss between HK$38 million and HK$42 million, a substantial improvement from the HK$135 million loss recorded in the previous year. This reduction is primarily attributed to a decrease in impairment losses on loan receivables. The financial results are based on preliminary assessments and have not yet been audited, with final results expected to be announced on March 31, 2025.

China Healthwise Holdings Delays Board Meeting to Finalize Annual Results

China Healthwise Holdings Limited has announced the postponement of its board meeting initially scheduled for March 25, 2025, to March 31, 2025. The delay is due to the need for additional time to finalize the company’s annual results for the year ending December 31, 2024. This postponement may impact stakeholders awaiting the annual results and any potential dividend announcements.

China Healthwise Extends Loan Repayment for Eternity Investment

China Healthwise Holdings Limited announced an extension of the repayment date for a financial facility provided to Eternity Investment Limited, a company involved in financial assets, property investment, and other sectors. The extension, agreed upon after negotiations, is expected to generate additional interest income and aligns with the company’s usual business practices, reflecting a strategic move to enhance shareholder value.

China Healthwise Holdings Schedules Board Meeting to Approve Annual Results

China Healthwise Holdings Limited has announced a board meeting scheduled for March 25, 2025, to discuss and approve the annual results for the year ending December 31, 2024. The meeting will also consider the recommendation of a final dividend and other related business matters, potentially impacting the company’s financial strategies and shareholder returns.